Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series

Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR)(+), human epidermal growth factor receptor (HE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Clin Oncol
Hauptverfasser: Schettini, Francesco, Santo, Irene De, Rea, Carmen G., Viggiani, Martina, Buono, Giuseppe, Angelis, Carmine De, Cardalesi, Cinzia, Lauria, Rossella, Giuliano, Mario, Forestieri, Valeria, Thomas, Guglielmo, Maione, Pierfrancesco, Limite, Gennaro, Accurso, Antonello, Malorni, Luca, Placido, Sabino De, Arpino, Grazia
Format: Artigo
Sprache:Inglês
Veröffentlicht: D.A. Spandidos 2020
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7087462/
https://ncbi.nlm.nih.gov/pubmed/32257203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2016
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge